NCT05423002 (CONE) is a NA clinical trial of Flickering light stimuli in Light Flashing, sponsored by University of Basel.

Who is sponsoring NCT05423002?

NCT05423002 is sponsored by University of Basel.

What drugs are being tested in NCT05423002?

Interventions in NCT05423002: Flickering light stimuli, Constant light stimuli, Dim light.

What condition does NCT05423002 study?

NCT05423002 studies Light Flashing.

Is NCT05423002 still recruiting?

NCT05423002 is currently status unknown. Last updated 21 June 2022.

Last reviewed 2022-06-21 · How we verify

NCT05423002: CONE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Different Color Lights on the Internal Clock and Alertness in Humans

Status unknown NA Last updated 21 June 2022

What this trial tests

NA trial testing Flickering light stimuli in Light Flashing in 68 participants. Status unknown.

Timeline

20 June 2022

Primary endpoint
15 March 2023

15 September 2023

Quick facts

Lead sponsor	University of Basel
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	68
Start date	20 June 2022
Primary completion	15 March 2023
Estimated completion	15 September 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Flickering light stimuli
Constant light stimuli
Dim light

Conditions studied

Light Flashing — all drugs for Light Flashing →

Sponsor

University of Basel

Who can join

Adults 18 to 35, any sex, with Light Flashing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to investigate the effects of cone-modulated light emitted from a visual display on human circadian physiology and cognitive performance in the evening.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Sex and Seasonal Variations in Melatonin Suppression and Alerting Response to Light.
Fazlali F, Lazar R, Yahya F, Stefani O, et al · · 2025 · cited 3× · PMID 41230024 · DOI 10.1210/jendso/bvaf155
Lack of strong evidence for cone photoreceptors' contribution to human melatonin suppression and alerting response to light.
Fazlali F, Lazar R, Yahya F, Epple C, et al · · 2025 · cited 3× · PMID 40687802 · DOI 10.1016/j.isci.2025.112983

Verify or expand the search:

Other University of Basel trials

Trials by the same sponsor.

NCT07160660 — Patients' Satisfaction and Clinical Investigation of Removable Partial Denture Anchorage With Extracoronal Adhesive Atta · enrolling by invitation
NCT06975020 — Pilot-Study for the Comparison of Biomarkers Between Regular Cannabis Users and Non-Users · NA · recruiting
NCT06848725 — Testing the Implementation of a Toolbox to Optimize Data Collection and Data Quality of the National Medical Quality Ind · NA · completed
NCT06473051 — Sustainable Improvement of INTERprofessional Care for Better Resident Outcomes · NA · active not recruiting
NCT06063135 — Effects of Physical Exercise Timing On Strength and Cardiometabolic Health · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05423002 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Basel
Last refreshed: 21 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05423002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing